However, a recent network meta-analysis of eight studies has identified that gefitinib is associated with longer OS than afatinib despite displaying a shorter PFS in EGFR-mutant NSCLC brain metastasis [21]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.